Somewhere around 200 million people worldwide live with age-related macular degeneration, and for those with the dry form of the disease, the prognosis has long been grim: a slow erosion of central vision with few ways to fight back. Now researchers at Finland’s Aalto University have demonstrated that a precisely controlled near-infrared laser, one that warms retinal tissue by just a few degrees without burning it, can switch on the eye’s own cellular cleanup systems. The results, published in Nature Communications, showed the technique working in both mice and pigs. A first-in-human safety trial is planned for spring 2026 in Finland, and as of late May 2026, enrollment details are expected imminently.
If the approach holds up in people, it could offer something the field has lacked for decades: a brief, non-invasive office procedure that slows the relentless march of dry AMD before it steals a patient’s ability to read, drive, or recognize faces.
What the Aalto team actually showed
The experiment centered on the retinal pigment epithelium, or RPE, a single layer of cells that sits behind the photoreceptors and acts as the retina’s maintenance crew. In dry AMD, the RPE gradually fails. Lipofuscin and drusen, forms of cellular waste, pile up and eventually kill the cells they smother, leaving behind patches of atrophy that correspond to permanent blind spots.
The Aalto team delivered near-infrared laser pulses to pig RPE cells while tracking tissue temperature in real time using electroretinography-based thermal dosimetry. That feedback loop kept the RPE within a narrow band above normal body heat but below roughly 45 degrees Celsius, the point at which thermal damage begins. By staying inside that safe window, the laser triggered what biologists call a hormetic stress response: a mild insult that prompts cells to mount a disproportionately strong defense.
Two families of molecular evidence confirmed the response. First, treated cells ramped up production of HSP70 and HSP90, heat-shock proteins that refold damaged proteins and shield cells from further stress. Second, the tissue showed increased LC3B-II, a marker of autophagosome formation, and decreased p62, a protein that builds up when cellular waste removal stalls. Together, those shifts indicate the RPE was actively clearing the kind of debris that defines dry AMD pathology.
“We are gently stressing the tissue to activate its own repair mechanisms rather than destroying it,” Prof. Ari Koskelainen, who led the research, said in an Aalto University statement.
The results held across two animal models. Earlier mouse work established the basic hormetic principle; the pig experiments, whose eyes more closely match the human eye in size and optics, confirmed that the thermal dosimetry system could scale. The publication’s technical appendix details the pulse parameters, safety margins, and calibration routines behind those findings.
Where this fits in a changing treatment landscape
For years, the standard advice for dry AMD patients amounted to AREDS2 vitamin supplements, not smoking, and regular monitoring. That changed in 2023 when the FDA approved two complement inhibitors for geographic atrophy, the advanced stage of dry AMD: pegcetacoplan (Syfovre, approved February 2023) and avacincaptad pegol (Izervay, approved August 2023). Both drugs slow the expansion of atrophy lesions, but they require repeated eye injections, carry a small risk of complications including rare cases of retinal vasculitis, and do not reverse vision already lost.
The Aalto laser operates on an entirely different principle. Rather than blocking a specific inflammatory cascade, it aims to reboot the RPE’s internal housekeeping. If it works in humans, it could complement existing drugs or, for patients in earlier stages of the disease before geographic atrophy sets in, potentially offer an intervention where none currently exists.
One other light-based device already occupies a related niche. The Valeda Light Delivery System received FDA De Novo classification for photobiomodulation in dry AMD, using multiwavelength light to influence mitochondrial activity and cellular metabolism. Valeda does not incorporate real-time thermal feedback. The Aalto system measures retinal temperature during each pulse and adjusts energy delivery on the fly, a distinction that could matter for safety and consistency. Whether that precision translates into better clinical outcomes is a question animal data alone cannot answer, and no head-to-head comparison between the two technologies has been conducted.
What still needs to be proven
The distance between a pig retina in a Finnish lab and a patient’s eye in a clinic is considerable, and several gaps remain.
Human safety is unconfirmed. The planned Phase 1 trial will focus on whether the procedure harms the retina, not on whether it slows disease. Investigators are expected to track visual acuity, retinal imaging, and electroretinography in the months after treatment. Only after a clean safety profile is established can larger trials test efficacy.
Trial details are sparse. As of late May 2026, no public filings from the Finnish Medicines Agency (Fimea) or the relevant ethics committee have appeared detailing the protocol, patient selection criteria, number of enrollees, or primary endpoints. It is not yet clear which stage of dry AMD will be targeted or whether retreatment is built into the design.
Durability is unknown. The pig studies captured heat-shock protein and autophagy marker changes in the days following treatment. Whether those effects last weeks or months, and whether repeated sessions would be needed, has not been established. If the hormetic effect fades quickly, a practical regimen might require multiple visits per year, raising questions about cost, access, and cumulative laser exposure.
Patient variability could complicate results. Dry AMD progresses at different rates depending on genetic background, systemic health, and environmental factors like smoking history. Human RPE cells, especially in elderly patients with years of oxidative damage, may respond differently to thermal stress than young, healthy pig tissue. The initial safety trial is unlikely to be large enough to identify which patient subgroups benefit most.
Raw data have not been shared. No dosimetry datasets or temperature time-series from the pig experiments have been publicly released beyond the summary figures in the journal article. Independent researchers who want to verify how tightly the system maintains its target temperature range will need access to those recordings, and no timeline for data sharing has been announced.
From tools that cut to tools that coax
The strongest piece of evidence here is the Nature Communications paper itself: peer-reviewed, with specific molecular readouts and a well-described engineering system. That is enough to justify serious attention, not certainty. The Aalto press materials provide useful context but are promotional by nature and should be weighed accordingly. And the FDA record for Valeda, while it does not validate or challenge the Aalto work directly, shows that regulators are willing to consider non-pharmacologic retinal interventions, a meaningful precedent.
For patients living with dry AMD today, the practical picture has not changed yet. The complement inhibitors remain the only approved drugs for geographic atrophy. AREDS2 supplements, regular eye exams, and lifestyle modifications are still the foundation of care for earlier stages. The Aalto thermal laser is a research-stage technology, promising in concept and backed by solid preclinical biology, but unproven in the organ that matters most: the human eye.
Still, the underlying idea carries weight. For decades, retinal lasers have been instruments of controlled destruction, burning tissue to seal leaking blood vessels or tack down detached retinas. The notion that a laser could instead nudge aging cells into cleaning house, coaxing them back toward health rather than cauterizing them into submission, represents a genuine conceptual shift. Whether it delivers on that promise will depend on what the Finnish trial reveals when its first patients sit down, rest their chins on the slit lamp, and let a carefully measured pulse of infrared light warm the back of their eyes by a few degrees.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
